<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=551791532206281&amp;ev=PageView&amp;noscript=1">
Rapid AI redefines stroke care

Redefining Stroke Care, Empowering Physicians to Push Boundaries and Improve Patient Outcomes

More than 650,000 scans from thousands of healthcare professionals in 50+ countries around the world have been analyzed. And that’s just the beginning of how we are continuing to redefine stroke care.

RAPID TIMES EVERY BRAIN

The Story of RapidAI

For 20+ years, most believed we had only a few hours after a stroke to provide treatment—but we were never satisfied with that thinking. We theorized that stroke evolution was highly variable, the conventional short treatment windows could be upended, and far more people with cerebrovascular disorders could be saved. We recognized that technology was the limiting factor even after an early NIH-funded, multicenter trial showed important advancements. We developed RAPID® (Rapid Processing of Perfusion and Diffusion) to address this need. Fast forward to today...

As the leader in brain imaging analysis, we are delivering proven software tools healthcare professionals around the world use to successfully identify and diagnose more cerebrovascular disorders than ever before possible. We take great pride in the role we continue to play in advancing stroke care and helping healthcare professionals save more lives.

Meet our team of innovators.

An experienced group of neurologists, radiologists, technologists and serial entrepreneurs.
Leadership Team
Meet our team of innovators
logos

The Only Validated and Clinically Proven Solution

RapidAI Validation
Timeline of Events

RapidAI Evolution Through The Years

2008

Dr. Greg Albers and Dr. Roland Bammer develop Rapid technology, the first fully automated image processing platform, at Stanford University with software engineer Matus Straka and funding from Sequoia Capital founder Don Valentine.
2009

Rapid MRI software installed in eight US and one European center for the NIH-sponsored DEFUSE 2 study.
2012

Dr. Albers and Dr. Bammer co-found the company iSchemaView (now named RapidAI) and purchase the rights to Rapid technology from Stanford University.
2012

The DEFUSE 2 study shows that by using Rapid MRI, physicians can identify stroke patients who respond favorably to endovascular clot removal up to 12 hours after stroke onset. Since then, RapidAI technology has been validated in more than a dozen multicenter clinical trials.
2012

Rapid CTP developed and installed in more than 70 North American and European sites for the SWIFT PRIME, EXTEND, and EXTEND-IA trials.
2013

Rapid CTP and Rapid MRI receive FDA clearance, allowing the platform to be used in hospitals throughout the U.S.
2014

SWIFT PRIME and EXTEND-IA trials document the highest favorable outcome rates ever obtained in a stroke trial and validate the use of Rapid CTP to select patients for thrombectomy within 6 hours of symptom onset.
2015

American Heart Association guidelines endorse thrombectomy as a new standard of care for stroke patients who can be treated up to 6 hours after onset. Rapid platform installed in more than 100 stroke centers.
2016

Rapid platform selected as the exclusive imaging selection method for the late-window trials, DAWN and DEFUSE 3.
2017

The Rapid platform achieves CE Mark certification, paving the way for use in the European Union.
2018

Based on the DAWN and DEFUSE 3 clinical trials that used Rapid imaging to select stroke patients for late-window treatment, the American Heart and American Stroke associations revise guidelines, extending the treatment window for acute stroke patients from 6 to 24 hours.
2018

The Rapid platform is approved for use in Canada, Australia, and New Zealand. Don Listwin is named CEO. Rapid ASPECTS announced, provides automated scoring to assess early signs of brain infarction. Rapid CTA receives FDA clearance.
2019

The EXTEND trial doubles the treatment window for intravenous tPA using Rapid CTP and Rapid MRI.
2019

Rapid CTA receives CE approval, becoming the first advanced imaging product indicated for localization of a detected large vessel occlusion (LVO).

Mexico, Brazil, Japan, Israel, and Vietnam join the list of 50+ countries that approve the use of Rapid platform.

2020

The Rapid platform is used in 1,500+ hospitals with over 650,000 scans processed to date. RapidAI launches Rapid ICH, a new product that uses artificial intelligence to quickly and automatically detect intracranial hemorrhages.
RapidAI is the future of stroke diagnosis
into the future of AI

Continuing to Help Physicians Diagnose Stroke in the Future.

Machine learning and other artificial intelligence (AI) techniques are changing medicine in profound ways. At RapidAI, we are using it to extract greater meaning from medical imaging data and to develop tools that ultimately help physicians improve patient care.

schedule a demo

Discover How You Can Use RapidAI

Talk with an Expert